Bind gains after NSCLC update

Bind Therapeutics Inc. (NASDAQ:BIND) jumped $1.91 (37%) to $7.06 on Thursday after reporting it had enrolled the first patient in a Phase II study of BIND-014 to treat non-small cell lung cancer (NSCLC) patients with a K-Ras ( KRAS) mutation or squamous histology, and offering the prospect that its timeline for Phase III trials could be accelerated.

President and CEO Scott Minick told BioCentury the two populations combined represent nearly half of all cases of NSCLC. He said Bind expects the Phase II data in late 2015 or early 2016, but noted it could start a Phase III trial sooner than that. ...